Overview

Bevacizumab in Multiple Phase I Combinations

Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab and lapatinib. The safety and effectiveness of these drug combinations will also be studied.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Antibodies
Antibodies, Monoclonal
Bevacizumab
Cetuximab
Erlotinib Hydrochloride
Lapatinib
Niacinamide
Sorafenib
Sunitinib
Trastuzumab